Avaliação da atividade do mirtenol do tratamento preventivo da cardiotoxidade aguda induzida por doxorrubicina

Abstract

Doxorubicin (DOA) Is an antineoplastic widely used for ts etiectiveness in various types of cancer, however, its use is considered due to its high cardiotoxic potential, mainly caused by oxidative stress and inflammation. Thus, natural products with antioxidant and anti-inflammatory properties can be an alternative for the treatment of cardiotoxícity induced by doxorubicin, in this sense, (-) Mirtenol, a bicyclic monoterpene alcohol, can be a promising candidate, since it has been highlighted in several studies for presenting precisely these properties. Thus, the objective of the present study was to evaluate the activity of myrtenol in the pretreatment of acute cardiotoxícity induced by doxorubicin, through the electrocardiogram and oxidative stress parameters. For this, male Wistar rats were used, being submitted to pre-treatment for seven consecutive days according to the group to which they were allocated, namely, Saline, Negative Control, Test 1 (mirtenol 25 mg/Kg), Test 2 (myrtenol 50 mg/Kg) and Test 3 (myrenol 100 mg/Kg), and on the 7th experimental day, cardiotoxícity was induced with doxorubicin, except for the saline group. The results of this study show that Mirtenol did not reduce the loss of body mass, nor the prolongation of the QT interval, nor the QTc, despite improving the arrhythmias. In oxidative stress parameters, myrtenol caused a considerable reduction in lipid hydroperoxide levels at doses of 25 mg/Kg (p < 0.01), 50 mg/Kg (p < 0.001) and 100 mg/Kg (p < O. 05) and increased glutathione peroxidase activity at doses of 50 mg/Kg (p < 0.01) and 100 mg/Kg (p < 0.05), but without effect on SOD activity. Given the above, we conclude that myrtenol does not prevent the loss of body mass and electrocardiographic changes caused by Doxorubicin, but it can improve arrhythmias and aspects related to antioxidant activity, however, more analyzes are needed for confirmatio.